AUTHORS
Satoshi Kaito, Toshihiro Banjo, PhD2, Karen Li3, Maxim Isaac Maron, MD, PhD4, Jahan Rahman5, Robert Bradley6, Omar Abdel-Wahab, MD7
AFFILIATIONS
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Fred Hutchinson Cancer Research Center, Seattle, United States
3 Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Fred Hutchinson Cancer Research Center, Seattle, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
ABSTRACT
The majority of protein-coding genes undergo alternative polyadenylation (APA), a process whereby 3’ end cleavage and polyadenylation of mRNA can occur at different sites. APA leads to RNA isoforms containing different 3’ untranslated regions (UTRs) which can modulate RNA stability, nuclear export, translation, and subcellular localization. APA is increasingly recognized as a critical layer in gene regulation. A few chemical inhibitors of APA have been previously described as therapeutics due to effects on inhibiting inflammatory cytokine production and promising anti-cancer properties, with AML being amongst the most sensitive cancers to APA inhibition. These include JTE-607, an inhibitor of the endonuclease CPSF3, and T4, a degrader of Cyclin K, a cofactor important for CDK12-mediated RNA polymerase II phosphorylation. Here we combine phenotypic screening with chemical genetics to identify a novel chemical regulator of APA with encouraging activity in AML.
We first generated an endogenous dual-luminescence APA reporter for positive-enrichment high-throughput screening by modifying the 3’ end of DICER1, a gene with APA sites that have been previously well characterized. Using CRISPR HDR, we inserted an in-frame HiBiT tag into the C-terminus of the endogenous DICER1 coding sequence to monitor total DICER1 protein produced from both short- and long-3’UTR isoforms. We also inserted an IRES-Firefly luciferase cassette within the DICER1 3’UTR between the proximal and distal polyadenylation (pA) sites. In this design, proximal pA site usage produces HiBiT signal alone, whereas distal pA site usage generates a long 3’UTR transcript containing the IRES-Firefly cassette, resulting in increased Firefly signal. Thus, the system provides a positive readout for compounds that promote distal pA site usage.
We verified the functionality of this dual reporter as T4 resulted in dose-dependent increases in Firefly luciferase, consistent with dose-dependent lengthening of the 3’UTR of DICER1. Following this, we performed a chemical screen of 50,000 drugs (including T4 and derivatives as positive controls) to identify compounds which lengthen the 3’UTR of DICER1. This revealed four compounds, each of which were validated to result in dose-dependent increases in Firefly luciferase individually. None of these four compounds have been previously described to modulate APA. We focused on the most potent of these four compounds, L369, as it resulted in APA modulation at nanomolar concentrations.
We next evaluated the impact of L369 on global 3’ UTR usage and intronic polyadenylation (IPA) using 3’ end RNA-seq. While T4 (but not L369) greatly enhanced IPA, both L369 and T4 resulted in global perturbations in 3’ UTR length without clear global trend in direction. To identify a cellular target of L369, we utilized forward genetic screens in DNA mismatch repair-deficient (HCT-116) cells. Cells were exposed to prolonged increasing concentrations of L369 to identify resistance mutations in genes encoding the potential drug target. Whole exome sequencing of 10 drug resistant clones identified recurrent mutations in CPSF1, a component of the Mammalian Polyadenylation Specific Factor complex which recognizes motifs in pre-mRNA upstream of the pA site. We verified that genetic depletion of CPSF1 increased Firefly luciferase signal in DICER1 APA dual reporter cell lines, to a comparable degree as L369 drug treatment.
To understand potential utility of L369 in cancer, we applied L369 to the BROAD PRISM screening platform (consisting of 900 DNA barcoded cell lines from >45 cancer types with genetic and functional genomic perturbation annotation). This revealed clear enrichment in drug sensitivity of AML cell lines relative to all other cell lines in the PRISM assay.
We confirmed the nanomolar efficacy of L369 against a panel of human AML cell lines and an AML mouse model created by KMT2A rearrangement while normal human CD34+ cells had ~5- to 10-fold lower sensitivity to L369. Moreover, L369 induced myeloid differentiation of a number of AML cell lines.
This study provides a new cellular tool for high throughput discovery of genetic and pharmacologic regulators of APA. We identify L369 as a novel potent APA modulatory drug with selective effects on AML over a wide array of cancer cell lines and normal hematopoietic cells. These data thereby also highlight the gene regulatory process of APA as an important therapeutic vulnerability in AML.
DISCLOSURES
Satoshi Kaito: No relevant conflicts of interest to declare.